John Harlow is joining the Morristown-based pure-play antibiotics company effective immediately where he will build upon its existing platform and enhance its portfolio with additional products that address therapeutic areas of critical need.

"From the beginning of this pandemic, Johnson & Johnson has recognized that no one is safe until everyone is safe, and we have been committed to equitable, global access to new COVID-19 vaccines," said J&J CEO and Chairman Alex Gorsky. "Our support for the COVAX Facility, combined with supplementary agreements with countries and regions, will help accelerate global progress toward ending the COVID-19 pandemic."

The mixed-use facility will accommodate all U.S. administrative, clinical, commercialization, manufacturing, and research and development activities.

This is the company's first opening since completing the acquisition of South Jersey alternative treatment center Compassionate Care Foundation in July.

When completed, the 82,000-square-foot building will feature custom-designed spaces for specialized pediatric care, women's services and wellness resources. The building will also include a commercial-grade kitchen to support the wellness center and host health education events.

This week, the state got over 10,000 doses of the J&J shot, according to New Jersey Health Commissioner Judith Persichilli, followed by an expected 51,700 doses next week.

Caroline Litchfield will be filling the role of Robert Davis, who is leaving the CFO position to become Merck’s new chief executive officer after that position is vacated by Kenneth Frazier.

"This federal investment will ensure South Jersey communities have continued access to quality health care and higher education,” Senator Bob Menendez said.

The significant gift will establish a research database of patient information from Cardiac Catheterization Laboratories procedures, cardiac intensive care units, vascular procedures, neuro-interventional procedures, structural heart disease procedures and electrophysiology procedures to research the best methods to treat cardiovascular patients based on real-time and real-world clinical data.

The collaboration will allow the teams to work together to make cell and gene therapies accessible and affordable for the patients who so desperately need them.

The collaboration will develop and enhance a broad array of high-quality orthopedic programs for medical, surgical, and related issues.

The company's employee matching donation campaign has provided over 600,000 meals during the COVID-19 crisis.